한글목차

세계 단클론항체(mAbs) 시장 규모는 2018년 1,151억 450만 달러로 평가되었고 2023년까지 복합 연간 성장률(CAGR) 12.0% 이상으로 성장할 것으로 예측됩니다.

연구개발비 증가

신약의 연구개발에 대한 세계 바이오의약품 지출 증가가 이 기간 시장 성장에 기여했습니다. 서유럽 국가의 규제 부담 증가와 비용 억제 강화로 기업 연구개발의 초점은 암이나 희소질환 등 투자대효과가 높은 질환에 대한 의약품 및 치료제 개발로 옮겨갔습니다. 전임상시험부터 승인까지의 바이오의약품기업의 연구개발비 중 바이오의약품 시장 성공에 필요한 프로세스 개발과 제조에 할당되는 비용의 비율은 1단계에서 13-17%, 승인 성공률은 4 -30%와 편차가 있는 것을 알았습니다. 최근 항체 전체의 성공률이 22%인 경우 연구개발에 대한 CMC 비용의 기여율은 17%를 나타낼 전망이며 결정되었습니다. 따라서 의약품의 R&D 비용 증가는 R&D 활동에 대한 투자와 자금 증가로 이어져 단일클론 항체 시장을 촉진시켰습니다.

목차

제1장 주요 요약

• 단클론항체(mAbs) - 시장의 매력과 거시경제 상황

제2장 목차

제3장 표제 목록

제4장 도표 일람

제5장 보고서 구성

제6장 시장 특징

• 일반적인 시장의 정의
• 개요
• 단클론항체(mAbs) 시장 정의와 세분화
• 시장 세분화 : 공급원별
  • 마우스
  • 키메라
  • 인간화
  • 인간
• 시장 세분화 : 용도별
  • 항암제
  • 면역학적
  • 감염증
  • 혈액 질환
  • 기타 용도
• 시장 세분화 : 최종 사용자별
  • 병원
  • 전문센터
  • 기타 최종 사용자

제7장 주요 시장 동향

• 표적요법과 병용요법에 대한 투자
• 시장에서의 혁신과 확대를 추진하기 위한 시장기업간의 전략적 파트너십과 콜라보레이션
• 치료에 혁명을 일으키는 연구개발 투자
• 혁신을 가속화하기 위한 인공지능의 통합
• 신규 치료법과 바이오시밀러의 제품 혁신에 의한 치료 옵션의 확산

제8장 단클론항체(mAbs) 시장 - 거시경제 시나리오

• COVID-19가 단클론항체(mAbs) 시장에 미치는 영향
• 우크라이나 전쟁이 단클론항체(mAbs) 시장에 미치는 영향
• 고인플레이션이 단클론항체(mAbs) 시장에 미치는 영향

제9장 시장 규모와 성장

• 시장 규모
• 시장 성장 실적(2018년-2023년)
  • 시장 성장 촉진요인(2018년-2023년)
  • 시장 성장 억제요인(2018년-2023년)
• 시장 성장 예측(2023년-2028년, 2033년)
  • 시장 성장 촉진요인(2023년-2028년)
  • 시장 성장 억제요인(2023년-2028년)

제10장 세계 단클론항체(mAbs) 시장 세분화

• 세계 단클론항체(mAbs) 시장 : 공급원별, 실적과 예측(2018년-2023년, 2028년, 2033년)
• 세계 단클론항체(mAbs) 시장 : 용도별, 실적과 예측(2018년-2023년, 2028년, 2033년)
• 세계 단클론항체(mAbs) 시장 : 최종 사용자별, 실적과 예측(2018년-2023년, 2028년, 2033년)

제11장 단클론항체(mAbs) 시장 : 지역별 및 국가별 분석

• 세계 단클론항체(mAbs) 시장 :지역별, 실적과 예측(2018년-2023년, 2028년, 2033년)
• 세계 단클론항체(mAbs) 시장 : 국가별, 실적과 예측(2018년-2023년, 2028년, 2033년)

제12장 아시아태평양 시장

제13장 서유럽 시장

제14장 동유럽 시장

제15장 북미 시장

제16장 남미 시장

제17장 중동 시장

제18장 아프리카 시장

제19장 경쟁 구도와 기업 프로파일

• 기업 프로파일
• Johnson & Johnson
  • 기업 개요
  • 제품 및 서비스
  • 비즈니스 전략
• Merck & Co., Inc.
  • 기업 개요
  • 제품 및 서비스
  • 비즈니스 전략
  • 재무 개요
• F. Hoffman-La Roche Ltd.
  • 기업 개요
  • 제품 및 서비스
  • 비즈니스 전략
  • 재무 개요
• Bristol Myers Squibb
  • 기업 개요
  • 제품 및 서비스
  • 비즈니스 전략
  • 재무 개요
• GlaxoSmithKline plc
  • 기업 개요
  • 제품 및 서비스
  • 비즈니스 전략
  • 재무실적

제20장 주요 인수합병(M&A)

• Syngene Acquired Stelis Biopharma
• Merck Acquired Prometheus Biosciences
• Biocon Biologics Acquired Viatris Inc
• Incyte Acquired Villaris Therapeutics
• FUJIFILM Corporation Acquired Atara Biotherapeutics
• Exelixis Inc. Acquired Gamamabs Pharma SA's AMHR2 Antibody Technology
• Sanofi Acquired Kymab Group Ltd.
• Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.
• Servier Acquired Symphogen A/S
• Gilead Sciences Acquired Forty Seven
• True North Acquired Stake In Biocon Biologics

제21장 파이프라인 분석

제22장 기회와 전략

• 2028년 세계 단클론항체(mAbs) 시장 - 가장 새로운 기회를 제공하는 국가
• 2028년 세계 단클론항체(mAbs) 시장 - 가장 새로운 기회를 제공하는 부문
• 2028년 세계 단클론항체(mAbs) 시장 - 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제23장 단클론항체 시장 : 결론 및 제안

• 결론
• 추천 사항
  • 제품
  • 장소
  • 가격
  • 프로모션
  • 사람들

제24장 부록

영문목차

Monoclonal antibodies (mAbs) are laboratory-produced antibodies that specifically bind to target molecules with high affinity, avidity and specificity. This binding results in inhibition of the target molecule's biological function by blocking its interaction with other receptor proteins or directing its destruction and elimination.

The monoclonal antibodies (mAbs) market consists of sales by entities (organizations, sole traders and partnerships), that produce monoclonal antibodies used to treat various medical conditions including cancer, inflammatory and autoimmune diseases.

The global monoclonal antibodies (mAbs) market was valued at $115,104.5 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 12.0%.

Increase In R&D Expenditure

The growth in global biopharmaceutical spending on research and development of new drugs contributed to the growth of the market during this period. The increased regulatory burden and greater cost containment in western countries led to shift in companies R&D focus to the development of drugs and therapeutics for diseases such as cancer and rare diseases with high return on investment. The percentage of a biopharmaceutical company's R&D out-of-pocket costs from pre-clinical to approval that needs to be allocated to process development and manufacturing for each biopharmaceutical market success was found to vary between 13-17% for Phase I to approval success rates of 4-30%. For the most recent antibody overall success rates of 22%, the CMC cost contribution to R&D was determined as 17%. Therefore, an increase in pharmaceutical R&D expenditure leads to increasing investments and funding for the R&D activities, which drove the monoclonal antibodies market.

Investment in Targeted and Combination Therapy

Companies in the monoclonal antibodies (mAbs) market are investing in targeted and combination therapy, which has been proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, in September 2022, the European Union (EU) granted approval for AstraZeneca's Evusheld (comprising tixagevimab and cilgavimab, previously known as AZD7442). This long-acting antibody combination was authorized for treating COVID-19 in adults and adolescents (aged 12 years and older, weighing at least 40 kg) who do not need supplemental oxygen and face an elevated risk of developing severe COVID-19. Also, in January 2020, European Commission has granted conditional marketing authorization for Polivy(R) (polatuzumab vedotin), in combination with bendamustine plus MabThera(R) (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.

The global monoclonal antibodies (mAbs) market is concentrated, with a few large player operating in the market. The top ten competitors in the market made up 41.8% of the total market in 2022.

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global monoclonal antibodies (mAbs) market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies based on local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Where is the largest and fastest-growing market for monoclonal antibodies (mAbs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The monoclonal antibodies (mAbs) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider monoclonal antibodies (mAbs) market; and compares it with other markets.

The report covers the following chapters:

• Introduction And Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by source, by application and by end-users market.
• Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the monoclonal antibodies (mAbs) market.
• Global Market Size and Growth - Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis - Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
• Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by source, by application and by end-users in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
• Regional Market Size And Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Key Mergers And Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
• Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for monoclonal antibodies (mAbs) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

• 1) By Source: Murine; Chimeric; Humanized; Human
• 2) By Application: Anti-Cancer; Immunological; Infectious Diseases; Hematological Disease; Other Applications
• 3) By End-Users: Hospitals; Specialty Centers; Other End-Users
• Companies Mentioned: Johnson & Johnson Inc.; Merck & Co., Inc.; F. Hoffman-La Roche Ltd.; Bristol Myers Squibb; GlaxoSmithKline plc
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; monoclonal antibodies (mAbs) indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Monoclonal Antibodies (mAbs) - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Monoclonal Antibodies (mAbs) Market Definition And Segmentations
• 6.4 Market Segmentation By Source
  • 6.4.1 Murine
  • 6.4.2 Chimeric
  • 6.4.3 Humanized
  • 6.4.4 Human
• 6.5 Market Segmentation By Application
  • 6.5.1 Anti-Cancer
  • 6.5.2 Immunological
  • 6.5.3 Infectious Disease
  • 6.5.4 Hematological Disease
  • 6.5.5 Other Applications
• 6.6 Market Segmentation By End-Users
  • 6.6.1 Hospitals
  • 6.6.2 Specialty Centers
  • 6.6.3 Other End-Users

7 Major Market Trends

• 7.1 Investment in Targeted and Combination Therapy
• 7.2 Strategic Partnerships And Collaborations Among Market Players To Drive Innovation and Expansion In The Market
• 7.3 R&D Investments Revolutionizing Treatment
• 7.4 Integration of Artificial Intelligence for Accelerated Innovation
• 7.5 Product Innovation In Novel Therapies and Biosimilars Expands Treatment Options

8 Monoclonal Antibodies (mAbs) Market - Macro-Economic Scenario

• 8.1 COVID-19 Impact On The Monoclonal Antibodies (mAbs) Market
• 8.2 Impact Of The War In Ukraine On The Monoclonal Antibodies (mAbs) Market
• 8.3 Impact Of High Inflation On The Monoclonal Antibodies (mAbs) Market

9 Global Market Size and Growth

• 9.1 Market Size
• 9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
  • 9.2.1 Market Drivers 2018 - 2023
  • 9.2.2 Market Restraints 2018 - 2023
• 9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
  • 9.3.1 Market Drivers 2023 - 2028
  • 9.3.2 Market Restraints 2023 - 2028

10 Global Monoclonal Antibodies (mAbs) Market Segmentation

• 10.1 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 10.2 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 10.3 Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

11 Monoclonal Antibodies (mAbs) Market, Regional and Country Analysis

• 11.1 Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 11.2 Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

• 12.1 Summary
  • 12.1.1 Market Overview
  • 12.1.2 Region Information
  • 12.1.3 Market Information
  • 12.1.4 Background Information
  • 12.1.5 Government Initiatives
  • 12.1.6 Regulations
  • 12.1.7 Regulatory Bodies
  • 12.1.8 Major Associations
  • 12.1.9 Taxes Levied
  • 12.1.10 Corporate Tax Structure
  • 12.1.11 Investments
  • 12.1.12 Major Companies
• 12.2 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.3 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.4 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.5 Asia-Pacific Monoclonal Antibodies (mAbs) Market: Country Analysis
• 12.6 China Market
• 12.7 Summary
  • 12.7.1 Market Overview
  • 12.7.2 Country Information
  • 12.7.3 Market Information
  • 12.7.4 Background Information
  • 12.7.5 Government Initiatives
  • 12.7.6 Regulations
  • 12.7.7 Regulatory Bodies
  • 12.7.8 Major Associations
  • 12.7.9 Taxes Levied
  • 12.7.10 Corporate Tax Structure
  • 12.7.11 Investments
  • 12.7.12 Major Companies
• 12.8 China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.9 China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.10 China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.11 India Market
• 12.12 India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.13 India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.14 India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.15 Japan Market
• 12.16 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.17 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.18 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.19 Australia Market
• 12.20 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.21 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.22 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.23 Indonesia Market
• 12.24 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.25 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.26 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.27 South Korea Market
• 12.28 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.29 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.30 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

• 13.1 Summary
  • 13.1.1 Market Overview
  • 13.1.2 Region Information
  • 13.1.3 Market Information
  • 13.1.4 Background Information
  • 13.1.5 Government Initiatives
  • 13.1.6 Regulations
  • 13.1.7 Regulatory Bodies
  • 13.1.8 Major Associations
  • 13.1.9 Taxes Levied
  • 13.1.10 Corporate tax structure
  • 13.1.11 Investments
  • 13.1.12 Major Companies
• 13.2 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.3 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.4 Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.5 Western Europe Monoclonal Antibodies (mAbs) Market: Country Analysis
• 13.6 UK Market
• 13.7 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.8 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.9 UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.10 Germany Market
• 13.11 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.12 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.13 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.14 France Market
• 13.15 France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.16 France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.17 France Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

• 14.1 Summary
  • 14.1.1 Market Overview
  • 14.1.2 Region Information
  • 14.1.3 Market Information
  • 14.1.4 Background Information
  • 14.1.5 Government Initiatives
  • 14.1.6 Regulations
  • 14.1.7 Regulatory Bodies
  • 14.1.8 Major Associations
  • 14.1.9 Taxes Levied
  • 14.1.10 Corporate Tax Structure
  • 14.1.11 Investments
  • 14.1.12 Major Companies
• 14.2 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.3 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.4 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.5 Eastern Europe Monoclonal Antibodies (mAbs) Market: Country Analysis
• 14.6 Russia Market
• 14.7 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.8 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.9 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

• 15.1 Summary
  • 15.1.1 Market Overview
  • 15.1.2 Region Information
  • 15.1.3 Market Information
  • 15.1.4 Background Information
  • 15.1.5 Government Initiatives
  • 15.1.6 Regulations
  • 15.1.7 Regulatory Bodies
  • 15.1.8 Major Associations
  • 15.1.9 Taxes Levied
  • 15.1.10 Corporate Tax Structure
  • 15.1.11 Investments
  • 15.1.12 Major Companies
• 15.2 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.3 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.4 North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.5 North America Monoclonal Antibodies (mAbs) Market: Country Analysis
• 15.6 USA Market
• 15.7 Summary
  • 15.7.1 Market Overview
  • 15.7.2 Country Information
  • 15.7.3 Market Information
  • 15.7.4 Background Information
  • 15.7.5 Government Initiatives
  • 15.7.6 Regulations
  • 15.7.7 Regulatory Bodies
  • 15.7.8 Major Associations
  • 15.7.9 Taxes Levied
  • 15.7.10 Corporate Tax Structure
  • 15.7.11 Investments
  • 15.7.12 Major Companies
• 15.8 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.9 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.10 USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

• 16.1 Summary
  • 16.1.1 Market Overview
  • 16.1.2 Region Information
  • 16.1.3 Market Information
  • 16.1.4 Background Information
  • 16.1.5 Government Initiatives
  • 16.1.6 Regulations
  • 16.1.7 Regulatory Bodies
  • 16.1.8 Major Associations
  • 16.1.9 Taxes Levied
  • 16.1.10 Corporate Tax Structure
  • 16.1.11 Investments
  • 16.1.12 Major Companies
• 16.2 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.3 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.4 South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.5 South America Monoclonal Antibodies (mAbs) Market: Country Analysis
• 16.6 Brazil Market
• 16.7 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.8 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.9 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

• 17.1 Summary
  • 17.1.1 Market Overview
  • 17.1.2 Region Information
  • 17.1.3 Market Information
  • 17.1.4 Background Information
  • 17.1.5 Government Initiatives
  • 17.1.6 Regulations
  • 17.1.7 Regulatory Bodies
  • 17.1.8 Major Associations
  • 17.1.9 Taxes Levied
  • 17.1.10 Corporate Tax Structure
  • 17.1.11 Investments
  • 17.1.12 Major Companies
• 17.2 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 17.3 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 17.4 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

• 18.1 Summary
  • 18.1.1 Market Overview
  • 18.1.2 Region Information
  • 18.1.3 Market Information
  • 18.1.4 Background Information
  • 18.1.5 Government Initiatives
  • 18.1.6 Regulations
  • 18.1.7 Regulatory Bodies
  • 18.1.8 Major Associations
  • 18.1.9 Taxes Levied
  • 18.1.10 Corporate Tax Structure
  • 18.1.11 Investment
  • 18.1.12 Major Companies
• 18.2 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 18.3 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 18.4 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape And Company Profiles

• 19.1 Company Profiles
• 19.2 Johnson & Johnson
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
  • 19.2.3 Business Strategy
• nal overview
• 19.3 Merck & Co., Inc.
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
  • 19.3.3 Business Strategy
  • 19.3.4 Financial Overview
• 19.4 F. Hoffman-La Roche Ltd.
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
  • 19.4.3 Business Strategy
  • 19.4.4 Financial Overview
• 19.5 Bristol Myers Squibb
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
  • 19.5.3 Business Strategy
  • 19.5.4 Financial Overview
• 19.6 GlaxoSmithKline plc
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
  • 19.6.3 Business Strategy
  • 19.6.4 Financial performance

20 Key Mergers And Acquisitions

• 20.1 Syngene Acquired Stelis Biopharma
• 20.2 Merck Acquired Prometheus Biosciences
• 20.3 Biocon Biologics Acquired Viatris Inc
• 20.4 Incyte Acquired Villaris Therapeutics
• 20.5 FUJIFILM Corporation Acquired Atara Biotherapeutics
• 20.6 Exelixis Inc. Acquired Gamamabs Pharma SA's AMHR2 Antibody Technology
• 20.7 Sanofi Acquired Kymab Group Ltd.
• 20.8 Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.
• 20.9 Servier Acquired Symphogen A/S
• 20.10 Gilead Sciences Acquired Forty Seven
• 20.11 True North Acquired Stake In Biocon Biologics

21 Pipeline Analysis

22 Opportunities And Strategies

• 22.1 Global Monoclonal Antibodies (mAbs) Market In 2028 - Countries Offering Most New Opportunities
• 22.2 Global Monoclonal Antibodies (mAbs) Market In 2028 - Segments Offering Most New Opportunities
• 22.3 Global Monoclonal Antibodies (mAbs) Market In 2028 - Growth Strategies
  • 22.3.1 Market Trend Based Strategies
  • 22.3.2 Competitor Strategies

23 Monoclonal Antibodies Market, Conclusions And Recommendations

• 23.1 Conclusions
• 23.2 Recommendations
  • 23.2.1 Product
  • 23.2.2 Place
  • 23.2.3 Price
  • 23.2.4 Promotion
  • 23.2.5 People

24 Appendix

• 24.1 Geographies Covered
• 24.2 Market Data Sources
• 24.3 Research Methodology
• 24.4 Currencies
• 24.5 The Business Research Company
• 24.6 Copyright and Disclaimer